Alkol – Madde Bağımlılığında Güncel Tedavi Yaklaşımlarından Naltrekson İmplantın Yeri
Özet
Alkol, opioid ve amfetamin bağımlılığında naltrekson implant kullanımı, oral tedaviye kıyasla daha yüksek uyum ve daha düşük nüks oranları sağlayarak etkili bir strateji sunmaktadır. Cerrahi yöntemle cilt altına yerleştirilen bu uzun salınımlı formlar, hedef kan düzeyini 2-3 ay boyunca koruyarak maddenin pekiştirici etkilerini sürekli olarak bloke eder. Genellikle iyi tolere edilmekle birlikte, tedavi süresince olası cerrahi komplikasyonlar ve karaciğer fonksiyonlarının takibi klinik açıdan önem arz etmektedir. Uzun vadede maliyet etkin bir çözüm sunan bu yöntem, bağımlılık tedavisinde hastaneye yatışları ve genel sağlık sorunlarını azaltma potansiyeline sahiptir.
Naltrexone implant use in alcohol, opioid, and amphetamine addiction provides an effective strategy by ensuring higher adherence and lower relapse rates compared to oral treatment. These long-acting forms, surgically implanted subcutaneously, continuously block the reinforcing effects of substances by maintaining target blood levels for 2-3 months. While generally well-tolerated, monitoring potential surgical complications and liver functions during treatment remains clinically significant. Offering a cost-effective solution in the long term, this method has the potential to reduce hospitalizations and general health problems in addiction treatment.
Referanslar
Uhl GR, Koob GF, Cable J. The neurobiology of addiction. Annals of the New York Academy of Sciences. 2019;1451(1):5-28.
Trigo JM, Martin-García E, Berrendero F, et al. The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence. 2010;108(3):183-94.
Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology. 2004;47 (Suppl 1):227-41.
Beveridge TJ, Smith HR, Nader MA, et al. Abstinence from chronic cocaine self-administration alters striatal dopamine systems in rhesus monkeys. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology. 2009;34(5):1162-71.
Koob GF, Le Moal M. Addiction and the brain antireward system. Annual Review of Psychology. 2008;59:29-53.
Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: Some current issues. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2008;363(1507):3137-46.
Martin WR, Gorodetzky CW, McClane TK. An experimental study in the treatment of narcotic addicts with cyclazocine. Clinical Pharmacology and Therapeutics. 1966;7(4):455-65.
O'Brien CP, Greenstein RA, Mintz J, et al. Clinical experience with naltrexone. The American Journal of Drug and Alcohol Abuse. 1975;2(3-4):365-77.
Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192-213.
Greenstein RA, Arndt IC, McLellan AT, et al. Naltrexone: A clinical perspective. The Journal of Clinical Psychiatry. 1984;45(9 Pt 2):25-8.
Cinemre B, Erdoğan A, Kulaksizoğlu B, et al. Comparison of oral naltrexone and naltrexone implant treatment in alcohol use disorders. Anatolian Journal of Psychiatry. 2020;21(0):1.
Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sciences. 1980;26(9):679-88.
Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-80.
Jayaram-Lindström N, Konstenius M, Eksborg S, et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology : Official publication of the American College of Neuropsychopharmacology. 2008;33(8):1856-63.
Jayaram-Lindström N, Wennberg P, Hurd YL, et al. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. Journal of Clinical Psychopharmacology. 2004;24(6):665-9.
Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychological Review. 1987;94(4):469-92.
Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. Journal of Neurochemistry. 1992;59(1):157-63.
Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opinion on Investigational Drugs. 2007;16(8):1285-94.
Azatian A, Papiasvilli A, Joseph H. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. Journal of Addictive Diseases. 1994;13(1):35-52.
Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug and Alcohol Review. 2000;19(1):41-8.
Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002;159(4):351-60.
Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: A randomized controlled trial. The American Journal of Psychiatry. 2012;169(5):531-6.
Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: A review. Current Opinion in Psychiatry. 2010;23(3):210-4.
Ramenskaya G, Shikh E, Arzamastsev A, et al. Pharmacokinetic study of the new domestic hypodermic form of naltrexone: Prodetoxon depot tablets. Pharmaceutical Chemistry Journal. 2005;39(1):1-3.
Kunøe N, Lobmaier P, Vederhus JK, et al. Retention in naltrexone implant treatment for opioid dependence. Drug and Alcohol Dependence. 2010;111(1-2):166-9.
Hulse GK, Ngo HT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biological Psychiatry. 2010;68(3):296-302.
Reece AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. Journal of Substance Abuse Treatment. 2009;37(3):256-65.
Malone M, McDonald R, Vittitow A, et al. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemporary Clinical Trials. 2019;81:102-9.
Akan M, Toplu SA, Cumurcu HB. Naltrekson İmplanta bağlı gelişmiş lokal komplikasyonlara multidisipliner yaklaşım: Olgu sunumu. Current Addiction Research. 2020;4(1):28-34.
Ngo HT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Archives of General Psychiatry. 2008;65(4):457-65.
Kruptisky E, Burakov A, Tsoy M, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction (Abingdon, England). 2007;102(7):1164-5.
Lintzeris N, Lee S, Scopelliti L, et al. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia. 2008;188(8):441-4.
Brewer C, Wong VS. Naltrexone: Report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addiction Biology. 2004;9(1):81-7.
Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002;159(4):351-60.
Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opinion on Investigational Drugs. 2007;16(8):1285-94.
